CEO Presentation to Bionomics’ Annual General Meeting 2010
It is a pleasure to warmly welcome you to Bionomics’ 2010 AGM. I also offer a special thank you to our interstate shareholders for making the effort to be here today. I am delighted to report on the sweeping progress your Company has made this year in delivering on Bionomics Limited
(ASX:BNO) strategy and advancing our position as a world-class, international clinical development Company, with validation of our technologies through a partnership with global Pharma Company Merck Serono, and a solid financial position.
Our overwhelming focus for the 09-10 financial year has been on building value in our drug candidate pipeline:
Our lead assets, anti-cancer agent BNC105 and anti-anxiety and depression drug BNC210 are both proceeding systematically through human trials here in Australia as well as in the US and Europe. As they do so they are attracting significant attention from potential global partners;
Our Multiple Sclerosis program, in partnership with the global Pharma subsidiary of Merck KGaA, Merck Serono, is also progressing strongly, bringing Bionomics Limited
(ASX:BNO) closer to achieving significant milestones under our 2008 Development and Licensing Agreement;
And in the background, Bionomics continues to leverage its technology platforms, Multicore®, Angene® and ionX®, to prioritise exciting new pipeline opportunities to bring online. In this respect we are very pleased with our continuing engagement with the CRC for Cancer Therapeutics.
Let me touch on the highlights of our clinical achievements over the last 12 months starting with the BNC105 program.
Download this document
